Importance of preventing cardiovascular events in patients with atherosclerosis predetermines the requirement for long-term antiplatelet therapy. Up to the present, acetylsalicylic acid (ASA) has been considered highly effective among antiplatelet drugs. In clinical practice, safety profile and good tolerability are particularly essential considering the need for chronic ASA treatment. New ASA forms have been searched for to minimize side effects and increase patients’ compliance with the treatment. Cardiomagnil is the only drug in Russia, which represents a combination of ASA and a non-absorbing antacid, magnesium hydroxide. High efficacy and availability of cardiomagnil along with its improved safety profile distinguish cardiomagnil from both other antiplatelet drugs and new ASA forms.

Patrono C, Bachmann F, Baigent C et al. Expert Consensus Document on the use of antiplatelet agents. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J. 2004 Jan;25 (2):166–81.